RiskReveal Assay Improved Lung Cancer Survival Outcomes
A gene-based test identified patients who saw significant survival benefits from adjuvant chemotherapy treatment.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Would you trust a gene test to decide whether to undergo post-surgery chemotherapy?
Presented in September 2026, clinical trial data revealed that the RiskReveal gene assay effectively identifies high-risk non-small cell lung cancer patients. Those categorized as high risk experienced significantly better outcomes when treated with platinum-based chemotherapy after surgery.
Why it matters
Standard markers for early-stage lung cancer recurrence have historically struggled to pinpoint which patients derive actual benefit from chemotherapy. By reliably identifying high-risk individuals, this assay could shift clinical standards toward more personalized adjuvant treatment strategies.
The RiskReveal assay uses polymerase chain reaction to analyze 14 genes in tumor tissue to categorize recurrence risk. In the AIM-HIGH trial, the high-risk group saw 96% two-year disease-free survival compared to 79% for those receiving only observation.
The players
World Congress on Lung Cancer
This is a major international medical conference where researchers and clinicians share advancements in the treatment and diagnosis of lung cancer.
The details
The test assesses 11 cancer genes and three reference genes to guide treatment decisions. High-risk patients receiving four cycles of platinum-based chemotherapy showed an 87% decrease in the risk for death in a long-term cohort study compared to those who did not.
Timeline
Researchers began tracking the 101-person patient cohort in 2012.
Findings were presented at the World Congress on Lung Cancer in September 2026.
The Big Picture
This research updates the findings established by the AIM-HIGH trial by providing a validated genetic screening tool to identify optimal candidates for platinum-based chemotherapy. It marks a departure from reliance on conventional markers that have failed to predict treatment benefit in early-stage lung cancer.
For patients diagnosed with early-stage non-small cell lung cancer, this testing may soon provide a clearer path to determine if adjuvant chemotherapy is necessary. It helps mitigate the physical toll of unnecessary treatments for low-risk patients while ensuring high-risk individuals receive timely care.
The takeaway
Genetic screening is increasingly critical for tailoring surgical aftercare in oncology. Patients should discuss specific molecular testing options with their oncologists to understand how their tumor profile influences the necessity of adjuvant therapy.
Further reading
Learn more about the latest diagnostic advancements in our Cancer section.
Live Poll
Would you trust a gene test to decide whether to undergo post-surgery chemotherapy?
